<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Commun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3915</journal-id><journal-id journal-id-type="pmc-domain">braincomms</journal-id><journal-id journal-id-type="publisher-id">braincomms</journal-id><journal-title-group><journal-title>Brain Communications</journal-title></journal-title-group><issn pub-type="epub">2632-1297</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10082557</article-id><article-id pub-id-type="pmcid-ver">PMC10082557.1</article-id><article-id pub-id-type="pmcaid">10082557</article-id><article-id pub-id-type="pmcaiid">10082557</article-id><article-id pub-id-type="pmid">37038497</article-id><article-id pub-id-type="doi">10.1093/braincomms/fcad092</article-id><article-id pub-id-type="publisher-id">fcad092</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1306-2708</contrib-id><name name-style="western"><surname>Woo</surname><given-names initials="MS">Marcel S</given-names></name><aff>
<institution>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20251</addr-line>, <country country="DE">Germany</country></aff><xref rid="fcad092-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayer</surname><given-names initials="C">Christina</given-names></name><aff>
<institution>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20251</addr-line>, <country country="DE">Germany</country></aff><xref rid="fcad092-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brehm</surname><given-names initials="TT">Thomas Theo</given-names></name><aff>
<institution>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>I. Department of Medicine, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Andersen</surname><given-names initials="G">Gabriele</given-names></name><aff>
<institution>Department of Occupational Safety and Health, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weigel</surname><given-names initials="A">Angelika</given-names></name><aff>
<institution>Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4220-3378</contrib-id><name name-style="western"><surname>L&#246;we</surname><given-names initials="B">Bernd</given-names></name><aff>
<institution>Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lohse</surname><given-names initials="AW">Ansgar W</given-names></name><aff>
<institution>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>I. Department of Medicine, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Addo</surname><given-names initials="MM">Marylyn M</given-names></name><aff>
<institution>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>I. Department of Medicine, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gerloff</surname><given-names initials="C">Christian</given-names></name><aff>
<institution>Department of Neurology, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20251</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2591-6387</contrib-id><name name-style="western"><surname>Knobloch</surname><given-names initials="JKM">Johannes K M</given-names></name><aff>
<institution>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>Institute of Medical Microbiology, Virology and Hygiene, Department for Infection Prevention and Control, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5033-1938</contrib-id><name name-style="western"><surname>Schulze zur Wiesch</surname><given-names initials="J">Julian</given-names></name><aff>
<institution>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><aff>
<institution>I. Department of Medicine, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20246</addr-line>, <country country="DE">Germany</country></aff><xref rid="fcad092-cor1" ref-type="corresp"/><xref rid="fcad092-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6380-2420</contrib-id><name name-style="western"><surname>Friese</surname><given-names initials="MA">Manuel A</given-names></name><aff>
<institution>Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg 20251</addr-line>, <country country="DE">Germany</country></aff><xref rid="fcad092-cor2" ref-type="corresp"/><xref rid="fcad092-FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="fcad092-cor1">Correspondence to: Julian Schulze zur Wiesch I. Department of Medicine University Medical Center Hamburg-Eppendorf Martinistra&#223;e 52, Hamburg 20246, Germany E-mail: <email>j.schulze-zur-wiesch@uke.de</email></corresp><corresp id="fcad092-cor2">Correspondence may also be addressed to: Manuel A. Friese Institute of Neuroimmunology and Multiple Sclerosis University Medical Center Hamburg-Eppendorf Falkenried 94, Hamburg 20251, Germany Email: <email>manuel.friese@zmnh.uni-hamburg.de</email></corresp><fn id="fcad092-FM1"><p>Marcel S Woo, Christina Mayer, Julian Schulze zur Wiesch and Manuel A Friese contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2023-03-25"><day>25</day><month>3</month><year>2023</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">430324</issue-id><elocation-id>fcad092</elocation-id><history><date date-type="received"><day>15</day><month>7</month><year>2022</year></date><date date-type="rev-recd"><day>16</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>09</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-15 14:25:37.323"><day>15</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcad092.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcad092.pdf"/><abstract><title>Abstract</title><p>Persistent somatic and neuropsychiatric symptoms have been frequently described in patients after infection with severe acute respiratory syndrome coronavirus 2 even after a benign clinical course of the acute infection during the early phases of the coronavirus severe acute respiratory syndrome coronavirus 2 pandemic and are part of Long COVID. The Omicron variant emerged in November 2021 and has rapidly become predominant due to its high infectivity and suboptimal vaccine cross-protection. The frequency of neuropsychiatric post-acute sequelae after infection with the severe acute respiratory syndrome coronavirus 2 Omicron and adequate vaccination status is not known. Here, we aimed to characterize post-acute symptoms in individuals with asymptomatic or mildly symptomatic breakthrough infection with severe acute respiratory syndrome coronavirus 2. These individuals had either proven infection with the Omicron variant (<italic toggle="yes">n</italic> = 157) or their infection occurred in 2022 where Omicron was the predominant variant of severe acute respiratory syndrome coronavirus 2 in Germany (<italic toggle="yes">n</italic> = 107). This monocentric cross-sectional study was conducted at the University Medical Center Hamburg-Eppendorf between 11 February 2022 and 11 April 2022. We employed questionnaires addressing self-reported somatic symptom burden (Somatic Symptom Scale 8) and neuropsychiatric symptoms including mood (Patient Health Questionnaire 2), anxiety (Generalized Anxiety Disorder 7), attention (Mindful Attention Awareness Scale) and fatigue (Fatigue Assessment Scale) in a cohort of hospital workers. Scores were compared between 175 individuals less than 4 weeks after positive testing for severe acute respiratory syndrome coronavirus 2, 88 individuals more than 4 weeks after positive testing and 87 severe acute respiratory syndrome coronavirus 2 uninfected controls. The majority (<italic toggle="yes">n</italic> = 313; 89.5%) of included individuals were vaccinated at least three times. After recovery from infection, no significant differences in scores assessing neuropsychiatric and somatic symptoms were detected between the three groups (severe acute respiratory syndrome coronavirus 2 uninfected controls, individuals less and more than 4 weeks after positive testing) independent of age, sex, preconditions and vaccination status. In addition, self-reported symptom burden did not significantly correlate with the number of vaccinations against severe acute respiratory syndrome coronavirus 2, time from recovery or the number of infections. Notably, in all three groups, the mean scores for each item of our questionnaire lay below the pathological threshold. Our data show that persistent neuropsychiatric and somatic symptoms after recovery from severe acute respiratory syndrome coronavirus 2 infection in fully vaccinated hospital workers do not occur more frequently than that in uninfected individuals. This will guide healthcare professionals in the clinical management of patients after recovery from breakthrough infections with severe acute respiratory syndrome coronavirus 2.</p></abstract><abstract abstract-type="teaser"><p>Woo and Mayer <italic toggle="yes">et al</italic>. investigated self-reported somatic and neuropsychiatric symptoms in a cross-sectional study of a closely monitored cohort of hospital workers after infection with the severe acute respiratory syndrome coronavirus 2 Omicron variant in comparison with uninfected individuals. No differences were detected between groups adjusted for age, sex, pre-existing conditions and vaccination status.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="fcad092_ga1" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcad092_ga1.jpg"/></fig>
</p></abstract><kwd-group><kwd>SARS-CoV-2 breakthrough infection</kwd><kwd>Omicron</kwd><kwd>Long COVID</kwd><kwd>neuropsychiatric deficits</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Deutsche Zentrum f&#252;r Infektionsforschung</institution><institution-id institution-id-type="doi">10.13039/501100010564</institution-id></institution-wrap></funding-source><award-id>FKZ8009801908</award-id><award-id>Fasttrack 1.921</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>FR1720/18-1</award-id><award-id>SFB1328</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Joachim-Herz-Foundation</institution><institution-id institution-id-type="doi">10.13039/100008662</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="fcad092-s0"><title>Introduction</title><p>Increasing numbers of individuals worldwide contracted an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), systematic analysis, diagnosis and treatment of potential post-acute symptoms and complications are of crucial importance.<sup><xref rid="fcad092-B1" ref-type="bibr">1</xref>,<xref rid="fcad092-B2" ref-type="bibr">2</xref></sup> Neuropsychiatric symptoms following acute infection can cause a high individual burden of disease<sup><xref rid="fcad092-B3" ref-type="bibr">3</xref></sup> and socio-economical costs due to the enormous number of people who experienced an infection.</p><p>Long COVID has been used as an umbrella term to describe the multitude of persistent symptoms attributed to long-term effects of a SARS-CoV-2 infection. These symptoms can affect nearly every organ system and include symptoms such as fatigue, headaches, shortness of breath, fever or cognitive impairment.<sup><xref rid="fcad092-B4" ref-type="bibr">4</xref></sup> Currently, there is no clear consensus regarding the definition of post-acute sequelae. Most commonly, the term Long COVID is used when symptoms persist for more than 4 weeks after the infection and cannot be explained by other causes.<sup><xref rid="fcad092-B5" ref-type="bibr">5</xref>,<xref rid="fcad092-B6" ref-type="bibr">6</xref></sup> During the first wave of the coronavirus SARS-CoV-2 (COVID-19) pandemic, when vaccines were not yet available, it has been estimated that 31&#8211;69% of patients suffered from post-acute sequelae.<sup><xref rid="fcad092-B7" ref-type="bibr">7-9</xref></sup> Certain risk factors have been identified during the acute disease in recent observational and retrospective cohort studies that might predict the development of Long COVID. These include type 2 diabetes, SARS-CoV-2 RNAemia, Epstein&#8211;Barr virus viraemia and specific autoantibodies.<sup><xref rid="fcad092-B10" ref-type="bibr">10</xref>,<xref rid="fcad092-B11" ref-type="bibr">11</xref></sup> Furthermore, female sex, high body mass index (BMI), social deprivation, advanced age, the presence of multiple comorbidities, a severe disease course and being unvaccinated predisposed to Long COVID.<sup><xref rid="fcad092-B5" ref-type="bibr">5</xref>,<xref rid="fcad092-B12" ref-type="bibr">12</xref></sup> Neurological deficits during acute COVID-19 range from unspecific dizziness, headache and nausea to acute encephalitis and cerebral ischaemia.<sup><xref rid="fcad092-B13" ref-type="bibr">13-15</xref></sup> Neuropsychiatric symptoms of Long COVID remain ill-defined due to unspecific clinical presentation and diagnostic findings. For individuals infected during the first waves of COVID-19 in 2020 and 2021, persistent neuropsychiatric deficits were associated with severe acute disease and pre-existing mental health conditions.<sup><xref rid="fcad092-B16" ref-type="bibr">16</xref>,<xref rid="fcad092-B17" ref-type="bibr">17</xref></sup> However, several studies also described prolonged neuropsychiatric deficits after mild SARS-CoV-2 infection in previously healthy individuals.<sup><xref rid="fcad092-B18" ref-type="bibr">18</xref>,<xref rid="fcad092-B19" ref-type="bibr">19</xref></sup></p><p>Due to the availability of vaccination, an increasing number of SARS-CoV-2 infections occur in vaccinated individuals and are referred to as breakthrough infections. The frequency and severity of post-COVID-19 symptoms in these breakthrough infections are still unclear. A recent study that utilized the US Department of Veterans Affairs national healthcare databases and compared the medical health records of more than 33 000 breakthrough infections with more than 6 million controls showed that vaccinations reduce the risk of post-acute death and Long COVID.<sup><xref rid="fcad092-B20" ref-type="bibr">20</xref></sup> However, vaccination only conferred partial protection since the incidence of post-acute sequelae was still elevated in comparison with healthy control groups.<sup><xref rid="fcad092-B20" ref-type="bibr">20</xref></sup> This is supported by other studies<sup><xref rid="fcad092-B21" ref-type="bibr">21</xref></sup> that observed only partial protection of vaccination against persistent symptoms. However, these studies did not stratify for different SARS-CoV-2 variants and were performed before emergence of the Omicron variant and before vaccination was available. This is particularly important for patients at risk for breakthrough infections such as individuals with a compromised immune system<sup><xref rid="fcad092-B22" ref-type="bibr">22-24</xref></sup> and individuals who are frequently exposed to infection such as hospital workers.</p><p>Here, we surveyed neuropsychiatric symptoms after recovery from breakthrough infections with the SARS-CoV-2 Omicron variant. In a large cohort of otherwise healthy hospital workers, we assessed post-acute sequelae after SARS-CoV-2 Omicron infection by self-reported scores for fatigue, attention, mood, anxiety and somatic symptoms and found no significant differences in every scoring system in comparison with individuals without SARS-CoV-2 infection. These findings were independent of age, sex, preconditions, number of vaccinations and infections and did not correlate with time after recovery.</p></sec><sec sec-type="materials|methods" id="fcad092-s1"><title>Materials and methods</title><sec id="fcad092-s1.1"><title>Study cohort</title><p>This monocentric cross-sectional analysis was performed on a longitudinally monitored cohort of hospital workers at the University Medical Center Hamburg-Eppendorf (UKE) in Germany<sup><xref rid="fcad092-B25" ref-type="bibr">25</xref></sup> between February 11 2022 and 11 April 2022. In total, 1575 eligible individuals with polymerase chain reaction (PCR)-confirmed infections were contacted via email by the department of infection prevention and asked to participate in an anonymized survey after recovering from acute SARS-CoV-2 infection. We received fully completed responses from 293 individuals. Of these, we excluded individuals who reported a PCR-confirmed infection with a SARS-CoV-2 variant other than the Omicron variant (<italic toggle="yes">n</italic> = 22), those who did not state the virus variant they were infected with and were infected before January 2022 where Omicron was not yet the predominant variant (<italic toggle="yes">n</italic> = 3) and those who were hospitalized during infection (<italic toggle="yes">n</italic> = 5). Subvariants of Omicron were not reported. We included 22 patients who were infected twice with SARS-CoV-2 of which at least one infection was with the Omicron variant. In total, 263 individuals were included after recovery from acute infection (175 less than 4 weeks after positive testing and 88 more than 4 weeks after positive testing). As a control group, we included 87 randomly selected hospital workers who did not have positive SARS-CoV-2 PCR results in their medical history and reported not having been infected before. In total, we included 350 individuals (242 females and 108 males) for the final analysis.</p></sec><sec id="fcad092-s1.2"><title>Assessment tools</title><p>The online questionnaires were distributed with the openly available tool <italic toggle="yes">limesurvey.org</italic>. The Fatigue Assessment Scale (FAS) score is a 10-item self-reported questionnaire.<sup><xref rid="fcad092-B26" ref-type="bibr">26</xref>,<xref rid="fcad092-B27" ref-type="bibr">27</xref></sup> It measures fatigue independent of depression and was validated multiple times in the general population, the working population and patients with chronic inflammatory diseases<sup><xref rid="fcad092-B27" ref-type="bibr">27</xref></sup> as well as cancer.<sup><xref rid="fcad092-B28" ref-type="bibr">28</xref></sup> A cut-off score above 21 points indicates fatigue. The Mindful Attention Awareness Scale (MAAS) was used to assess attention in our study cohort.<sup><xref rid="fcad092-B29" ref-type="bibr">29</xref></sup> It is a 15-item questionnaire that measures the frequency of mindful states in day-to-day life, using both general and situation-specific statements. Higher scores in the MAAS indicate higher attention.<sup><xref rid="fcad092-B30" ref-type="bibr">30</xref></sup> The Patient Health Questionnaire 2 (PHQ-2) addresses the two core criteria of depressive disorders: the loss of interest and feeling depressed. The PHQ-2 has been reported to have a high sensitivity for depressive disorders and detects changes with a performance like other longer depression scales.<sup><xref rid="fcad092-B31" ref-type="bibr">31</xref></sup> The Generalized Anxiety Disorder 7 (GAD-7) is a well-established 7-item questionnaire to screen for anxiety severity. The score has been validated for the four most common anxiety disorders in clinical practice: generalized anxiety, panic, social anxiety and post-traumatic stress disorder. Sum scores range from 0 to 21, and a score above 10 is an indicator of the presence of an anxiety disorder.<sup><xref rid="fcad092-B32" ref-type="bibr">32</xref>,<xref rid="fcad092-B33" ref-type="bibr">33</xref></sup> For the self-reported burden of somatic symptoms, we applied the Somatic Symptom Scale 8 (SSS-8), which addresses somatic symptoms falling into one of the four following groups: cardiopulmonary, gastrointestinal, pain and general.<sup><xref rid="fcad092-B34" ref-type="bibr">34</xref></sup> According to the score reached in the SSS-8, individuals can be categorized into five groups of somatic symptom burden: no to minimal (0&#8211;3 points), low (4&#8211;7 points), medium (8&#8211;11 points), high (12&#8211;15 points) and very high (16&#8211;32 points). The questionnaires are provided in the <xref rid="app1" ref-type="app">Appendix I</xref>.</p></sec><sec id="fcad092-s1.3"><title>SARS-CoV-2 diagnostic procedures</title><p>All employees of the UKE, a tertiary care centre, were screened twice weekly for SARS-CoV-2 infection by reverse transcription PCR (RT-PCR) of nasopharyngeal swabs or gargle samples throughout the COVID-19 pandemic to prevent nosocomial transmission to coworkers and vulnerable patients. Thus, also asymptomatic and oligosymptomatic infections were detected with high sensitivity. Only study participants who reported a SARS-CoV-2 infection diagnosed by RT-PCR were included in the study.</p></sec><sec id="fcad092-s1.4"><title>Statistical analysis</title><p>All statistical analyses were performed using the R environment (version 4.0.3). Difference in age and sex distribution as well as number of pre-existing conditions and vaccination status between groups were calculated by chi-square test. To assess the impact of Omicron infection less and more than 4 weeks after positive PCR on self-reported somatic and neuropsychiatric symptoms, we fitted a linear regression model with the sum score as dependent and recovery from Omicron infection (less versus more than 4 weeks) as independent variables. We controlled for sex (male and female), age groups (&lt;30, 30&#8211;40, 40&#8211;50 and &gt;50 years), vaccination status and the number of pre-existing conditions as independent variables. To test the interaction of independent variables with recovery from Omicron SARS-CoV-2, we performed one-way ANCOVA. We corrected for multiple comparisons by false discovery rate (FDR) adjustment. Correlation analysis between time from recovery and number of vaccinations with the sums of each score were performed using Pearson&#8217;s correlation. To analyse the minimum mean difference between groups that could have been missed by each questionnaire, we calculated the effect size using a power of 0.8, a significance level of 0.05 and the respective group sizes and multiplied it with the pooled standard deviation.</p></sec><sec id="fcad092-s1.5"><title>Ethical approval</title><p>The study was approved by the &#8216;&#196;rztekammer Hamburg&#8217; with the registration number 2022-300157-WF.</p></sec><sec id="fcad092-s1.6"><title>Patient consent</title><p>All individuals gave consent for participation, data analysis and publication.</p></sec></sec><sec sec-type="results" id="fcad092-s2"><title>Results</title><sec id="fcad092-s2.1"><title>Recruitment and study cohort</title><p>We aimed to survey neuropsychiatric and somatic disease burden in an unbiased and self-reported fashion after infection with the SARS-CoV-2 Omicron variant in a cohort of highly exposed individuals who are critical to the healthcare system.<sup><xref rid="fcad092-B1" ref-type="bibr">1</xref></sup> To do so, we conducted a monocentric study and made use of a representative cohort of hospital workers with predominantly up-to-date vaccination status after proven infection that mainly occurred as breakthrough infection. All participants underwent regular PCR testing for SARS-CoV-2 that ensured also the detection of asymptomatically infected individuals.<sup><xref rid="fcad092-B35" ref-type="bibr">35-37</xref></sup> The algorithm of inclusion and exclusion criteria is depicted in <xref rid="fcad092-F1" ref-type="fig">Fig.&#160;1</xref>. In total, we included 350 individuals aged between 18 and 69 years. A total of 263 participants had a PCR-confirmed infection with SARS-CoV-2. Of these, 156 individuals had an infection with the Omicron variant. A total of 107 individuals did not report their virus variant but were infected in 2022 when COVID-19 in Germany was almost exclusively caused by the Omicron variant (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.rki.de" ext-link-type="uri">www.rki.de</ext-link>). Thus, they were assumed to be infected with the Omicron variant. In addition, we randomly recruited 87 hospital workers as controls who have not been infected with SARS-CoV-2.</p><fig position="float" id="fcad092-F1" fig-type="figure" orientation="portrait"><label>Figure&#160;1</label><caption><p>Flowchart of inclusion criteria and final cohort.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcad092f1.jpg"/></fig><p>For further analysis, we stratified participants into three groups: individuals with recovery from acute infection who were included less than 4 weeks after positive PCR testing (female, <italic toggle="yes">n</italic> = 126; male, <italic toggle="yes">n</italic> = 49; 72% female; mean duration after infection = 25.6 &#177; 10.6 days), participants in the post-acute phase over 4 weeks after positive testing for SARS-CoV-2 (female, <italic toggle="yes">n</italic> = 63; male, <italic toggle="yes">n</italic> = 25; 72% female; mean duration after infection = 75.5 &#177; 37.7 days) and uninfected participants (53 female, 34 male, 61% female). In all groups, female participation was higher than male participation. All three groups had a similar age distribution (<italic toggle="yes">&#967;</italic><sup>2</sup> = 0.05, <italic toggle="yes">P</italic> = 1), sex distribution <italic toggle="yes">&#967;</italic><sup>2</sup> = 0.04, <italic toggle="yes">P</italic> = 0.98) and number of pre-existing conditions (<italic toggle="yes">&#967;</italic><sup>2</sup> = 0.03, <italic toggle="yes">P</italic> = 1) and were mostly vaccinated three times <italic toggle="yes">&#967;</italic><sup>2</sup> = 0.09, <italic toggle="yes">P</italic> = 1). Characteristics of included participants are summarized in <xref rid="fcad092-T1" ref-type="table">Table&#160;1</xref>. Together, the 350 included study participants were predominantly healthy hospital workers with almost no preconditions and mostly up-to-date vaccination status.</p><table-wrap position="float" id="fcad092-T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> total</th><th align="center" rowspan="1" colspan="1">Not infected</th><th align="center" rowspan="1" colspan="1">&lt;4 weeks after recovery</th><th align="center" rowspan="1" colspan="1">&gt;4 weeks after recovery</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Sex <italic toggle="yes">N</italic> (%)</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">242 (69.1)</td><td rowspan="1" colspan="1">53 (21.9)</td><td rowspan="1" colspan="1">126 (52.1)</td><td rowspan="1" colspan="1">63 (26.0)</td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">108 (30.9)</td><td rowspan="1" colspan="1">34 (31.5)</td><td rowspan="1" colspan="1">49 (45.4)</td><td rowspan="1" colspan="1">25 (23.1)</td></tr><tr><td rowspan="4" colspan="1">Age (years) <italic toggle="yes">N</italic> (%)</td><td rowspan="1" colspan="1">&lt;30</td><td rowspan="1" colspan="1">153 (43.7)</td><td rowspan="1" colspan="1">36 (23.5)</td><td rowspan="1" colspan="1">86 (56.2)</td><td rowspan="1" colspan="1">31 (20.3)</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39</td><td rowspan="1" colspan="1">94 (26.9)</td><td rowspan="1" colspan="1">21(22.3)</td><td rowspan="1" colspan="1">47 (50.0)</td><td rowspan="1" colspan="1">26 (27.7)</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49</td><td rowspan="1" colspan="1">66 (18.9)</td><td rowspan="1" colspan="1">19 (28.8)</td><td rowspan="1" colspan="1">27 (40.9)</td><td rowspan="1" colspan="1">20 (30.3)</td></tr><tr><td rowspan="1" colspan="1">&gt;50</td><td rowspan="1" colspan="1">37 (10.5)</td><td rowspan="1" colspan="1">11 (29.7)</td><td rowspan="1" colspan="1">15 (40.6)</td><td rowspan="1" colspan="1">11 (29.7)</td></tr><tr><td rowspan="5" colspan="1">Vaccinations <italic toggle="yes">N</italic> (%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11(3.1)</td><td rowspan="1" colspan="1">3 (27.3)</td><td rowspan="1" colspan="1">3 (27.3)</td><td rowspan="1" colspan="1">5 (45.4)</td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">4 (1.1)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (50.0)</td><td rowspan="1" colspan="1">2 (50.0)</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">22 (6.3)</td><td rowspan="1" colspan="1">2 (9.1)</td><td rowspan="1" colspan="1">14 (63.6)</td><td rowspan="1" colspan="1">6 (27.3)</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">310 (88.6)</td><td rowspan="1" colspan="1">82 (26.5)</td><td rowspan="1" colspan="1">154 (49.7)</td><td rowspan="1" colspan="1">74 (23.8)</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3 (0.9)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (66.6)</td><td rowspan="1" colspan="1">1 (33.4)</td></tr><tr><td rowspan="5" colspan="1">Pre-existing conditions <italic toggle="yes">N</italic> (%)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">239 (68.3)</td><td rowspan="1" colspan="1">62 (25.9)</td><td rowspan="1" colspan="1">119 (49.8)</td><td rowspan="1" colspan="1">58 (24.3)</td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">74 (21.1)</td><td rowspan="1" colspan="1">17 (23.0)</td><td rowspan="1" colspan="1">39 (52.7)</td><td rowspan="1" colspan="1">18 (24.3)</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">25 (7.1)</td><td rowspan="1" colspan="1">5 (20.0)</td><td rowspan="1" colspan="1">13 (52.0)</td><td rowspan="1" colspan="1">7 (28.0)</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">10 (2.9)</td><td rowspan="1" colspan="1">3 (30.0)</td><td rowspan="1" colspan="1">3 (30.0)</td><td rowspan="1" colspan="1">4 (40.0)</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2 (0.6)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (50.0)</td><td rowspan="1" colspan="1">1 (50.0)</td></tr><tr><td rowspan="3" colspan="1">SARS-CoV-2 <italic toggle="yes">N</italic> (%)</td><td rowspan="1" colspan="1">Confirmed Omicron by PCR</td><td rowspan="1" colspan="1">156 (44.6)</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">99 (63.5)</td><td rowspan="1" colspan="1">57 (36.5)</td></tr><tr><td rowspan="1" colspan="1">Infection in 2022</td><td rowspan="1" colspan="1">107 (30.6)</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">76 (71.0)</td><td rowspan="1" colspan="1">31 (29.0)</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">87 (24.8)</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr></tbody></table></table-wrap></sec><sec id="fcad092-s2.2"><title>Assessing neuropsychiatric sequelae</title><p>To systematically survey a wide range of neuropsychiatric domains with well-established tests, we assessed somatic and neuropsychiatric symptoms by conducting an online survey. This allowed us to anonymously receive an authentic insight into symptoms. First, we addressed somatic symptoms with the SSS-8.<sup><xref rid="fcad092-B34" ref-type="bibr">34</xref></sup> These symptoms include headache, abdominal pain, limb pain, back pain, sleep disturbances, fatigue, dizziness and shortness of breath. We did not find differences in self-reported items between participants less than 4 weeks (<italic toggle="yes">P</italic> = 0.27) and participants more than 4 weeks after recovery as well as in comparison with uninfected controls (<italic toggle="yes">P</italic> = 0.091; <xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2A</xref>).</p><fig position="float" id="fcad092-F2" fig-type="figure" orientation="portrait"><label>Figure&#160;2</label><caption><p>
<bold>No differences in self-reported somatic and neuropsychiatric deficits after recovery from Omicron.</bold> (<bold>A&#8211;E</bold>) Comparison of SSS-8 (<bold>A</bold>; healthy versus &lt;4 weeks <italic toggle="yes">P</italic> = 0.27, healthy versus &gt;4 weeks <italic toggle="yes">P</italic> = 0.091), FAS (<bold>B</bold>; healthy versus &lt;4 weeks <italic toggle="yes">P</italic> = 0.76, healthy versus &gt;4 weeks <italic toggle="yes">P</italic> = 0.69), GAD-7 (<bold>C</bold>; healthy versus &lt;4 weeks <italic toggle="yes">P</italic> = 0.46, healthy versus &gt;4 weeks <italic toggle="yes">P</italic> = 0.9), MAAS (<bold>D</bold>; healthy versus &lt;4 weeks <italic toggle="yes">P</italic> = 0.2, healthy versus &gt;4 weeks <italic toggle="yes">P</italic> = 0.59), PHQ-2 (<bold>E</bold>; healthy versus &lt;4 weeks <italic toggle="yes">P</italic> = 0.07, healthy versus &gt;4 weeks <italic toggle="yes">P</italic> = 0.41) between individuals that did not contract SARS-CoV-2 infection and individuals less and more than 4 weeks after recovery from SARS-CoV-2 infection. Linear regression model with correction for sex and age was used for statistical analysis. (<bold>F&#8211;J</bold>) Correlation analysis of months after recovery and SSS-8 (<bold>F</bold>; &lt;30 years <italic toggle="yes">P</italic> = 0.56, 30&#8211;39 years <italic toggle="yes">P</italic> = 0.74, 40&#8211;49 years <italic toggle="yes">P</italic> = 0.11, &gt;50 years <italic toggle="yes">P</italic> = 0.38), FAS (<bold>G</bold>; &lt;30 years <italic toggle="yes">P</italic> = 0.59, 30&#8211;39 years <italic toggle="yes">P</italic> = 0.23, 40&#8211;49 years <italic toggle="yes">P</italic> = 0.75, &gt;50 years <italic toggle="yes">P</italic> = 0.98), GAD-7 (<bold>H</bold>; &lt;30 years <italic toggle="yes">P</italic> = 0.89, 30&#8211;39 years <italic toggle="yes">P</italic> = 0.67, 40&#8211;49 years <italic toggle="yes">P</italic> = 0.96, &gt;50 years <italic toggle="yes">P</italic> = 0.78), MAAS (<bold>I</bold>; &lt;30 years <italic toggle="yes">P</italic> = 0.59, 30&#8211;39 years <italic toggle="yes">P</italic> = 0.97, 40&#8211;49 years <italic toggle="yes">P</italic> = 0.5, &gt;50 years <italic toggle="yes">P</italic> = 0.29) and PHQ-2 (<bold>J</bold>; &lt;30 years <italic toggle="yes">P</italic> = 0.49, 30&#8211;39 years <italic toggle="yes">P</italic> = 0.53, 40&#8211;49 years <italic toggle="yes">P</italic> = 0.99, &gt;50 years <italic toggle="yes">P</italic> = 0.11) scores. Each data point represents an individual. Statistical analysis was performed by Pearson correlation analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcad092f2.jpg"/></fig><p>Next, we quantified neuropsychiatric symptoms with a variety of established and commonly used screening questionnaires. We assessed fatigue that is reported to be one of the most common symptoms of Long COVID.<sup><xref rid="fcad092-B38" ref-type="bibr">38</xref></sup> By employing the Fatigue Assessment Score (FAS), we observed no significant differences between uninfected controls and individuals that recovered from infection with the SARS-CoV-2 Omicron variant that was also independent of time after infection (&lt;4 weeks after recovery <italic toggle="yes">P</italic> = 0.69; &gt;4 weeks after recovery <italic toggle="yes">P</italic> = 0.76). Of note, the mean FAS score for all groups was below 21 points, which is commonly used as a threshold for the diagnosis of fatigue (<xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2B</xref>). Subsequently, we evaluated anxiety by applying the GAD-7 questionnaire. A total score of 10 or more indicates the presence of an anxiety disorder. Again, a previous mild SARS-CoV-2 infection with the Omicron variant did not influence the scoring in the anxiety levels as assessed with the GAD-7 after recovery from acute infection in vaccinated individuals (&lt;4 weeks <italic toggle="yes">P</italic> = 0.2; &gt;4 weeks <italic toggle="yes">P</italic> = 0.59; <xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2C</xref>). Additionally, we assessed attention and awareness by including the MAAS in the survey with lower scores indicating lower levels of attention. We were not able to detect significant differences between uninfected controls and patients after recovery from mild Omicron breakthrough infection (&lt;4 weeks <italic toggle="yes">P</italic> = 0.9; &gt;4 weeks <italic toggle="yes">P</italic> = 0.46; <xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2D</xref>). We asked whether infected individuals were more likely to show signs of depression as assessed with the PHQ-2 and observed no differences between infected individuals and uninfected controls (&lt;4 weeks after recovery <italic toggle="yes">P</italic> = 0.067; &gt;4 weeks after recovery <italic toggle="yes">P</italic> = 0.41; <xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2E</xref>). The pathological threshold for each questionnaire and the mean score and standard deviation reached by each group (non-infected, &lt;4 weeks after infection, &gt;4 weeks after infection) are summarized in <xref rid="fcad092-T2" ref-type="table">Table&#160;2</xref>. Furthermore, for each questionnaire, we analysed the minimum mean difference between non-infected individuals and &lt;4 weeks after infection as well as non-infected and &gt;4 weeks after infection that would have been necessary to reach significance given our sample sizes, a power of 0.8, a significance level of 0.05 and the pooled standard deviation (<xref rid="fcad092-T2" ref-type="table">Table&#160;2</xref>).</p><table-wrap position="float" id="fcad092-T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Descriptive statistics for whole cohort</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Test</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">Mean difference compared with not infected</th><th align="center" rowspan="1" colspan="1">Minimum mean difference for detection</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">
<bold>FAS (pathological threshold &gt; 21)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">12.5</td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after recovery</td><td rowspan="1" colspan="1">12.7</td><td rowspan="1" colspan="1">5.0</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">1.5</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after recovery</td><td rowspan="1" colspan="1">13.3</td><td rowspan="1" colspan="1">5.3</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">1.8</td></tr><tr><td colspan="5" rowspan="1">
<bold>MAAS (pathological threshold &lt; 17)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">24.6</td><td rowspan="1" colspan="1">12.4</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after recovery</td><td rowspan="1" colspan="1">24.1</td><td rowspan="1" colspan="1">13.4</td><td rowspan="1" colspan="1">&#8722;0.5</td><td rowspan="1" colspan="1">4.2</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after recovery</td><td rowspan="1" colspan="1">25.7</td><td rowspan="1" colspan="1">13.6</td><td rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">4.9</td></tr><tr><td colspan="5" rowspan="1">
<bold>GAD-7 (pathological threshold &gt; 10)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">4.4</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after recovery</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">4.0</td><td rowspan="1" colspan="1">&#8722;0.7</td><td rowspan="1" colspan="1">1.4</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after recovery</td><td rowspan="1" colspan="1">4.2</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">&#8722;0.2</td><td rowspan="1" colspan="1">1.8</td></tr><tr><td colspan="5" rowspan="1">
<bold>PHQ-2 (pathological threshold &gt; 2)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after recovery</td><td rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">&#8722;0.3</td><td rowspan="1" colspan="1">0.5</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after recovery</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">&#8722;0.1</td><td rowspan="1" colspan="1">0.6</td></tr><tr><td colspan="5" rowspan="1">
<bold>SSS-8 (high burden &gt; 11)</bold>
</td></tr><tr><td rowspan="1" colspan="1">Not infected</td><td rowspan="1" colspan="1">7.5</td><td rowspan="1" colspan="1">5.9</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after recovery</td><td rowspan="1" colspan="1">6.9</td><td rowspan="1" colspan="1">5.6</td><td rowspan="1" colspan="1">&#8722;0.6</td><td rowspan="1" colspan="1">1.9</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after recovery</td><td rowspan="1" colspan="1">6.4</td><td rowspan="1" colspan="1">5.3</td><td rowspan="1" colspan="1">&#8722;1.1</td><td rowspan="1" colspan="1">2.1</td></tr></tbody></table></table-wrap><p>In addition to acute and post-acute infection, we tested the presence of several preconditions, such as sex, age and the number of vaccinations as independent variables for each score (results are shown in <xref rid="fcad092-T3" ref-type="table">Table&#160;3</xref>). For significant associations, we calculated the interaction with recovery less and more than 4 weeks after infection. Of note, we did not find any significant interactions of SARS-CoV-2 infection with age, sex, vaccination status, the number of preconditions and the number of infections (results are shown in <xref rid="fcad092-T4" ref-type="table">Table&#160;4</xref>). Thus, the lack of differences in self-reported somatic and neuropsychiatric symptoms between uninfected controls and individuals with acute or post-acute infection is independent of age, sex, vaccination status, the number of preconditions and the number of infections.</p><table-wrap position="float" id="fcad092-T3" orientation="portrait"><label>Table&#160;3</label><caption><p>Descriptive statistics by subgroups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Estimate</th><th align="center" rowspan="1" colspan="1">SE</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>-statistics</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th><th align="center" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td colspan="6" rowspan="1">
<bold>FAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.26</td><td rowspan="1" colspan="1">0.62</td><td rowspan="1" colspan="1">&#8722;0.42</td><td rowspan="1" colspan="1">0.76</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after infection</td><td rowspan="1" colspan="1">0.44</td><td rowspan="1" colspan="1">0.71</td><td rowspan="1" colspan="1">0.62</td><td rowspan="1" colspan="1">0.69</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 30&#8211;39</td><td rowspan="1" colspan="1">&#8722;0.72</td><td rowspan="1" colspan="1">0.62</td><td rowspan="1" colspan="1">&#8722;1.16</td><td rowspan="1" colspan="1">0.37</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 40&#8211;49</td><td rowspan="1" colspan="1">&#8722;1.45</td><td rowspan="1" colspan="1">0.69</td><td rowspan="1" colspan="1">&#8722;2.09</td><td rowspan="1" colspan="1">0.084</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age &gt;50</td><td rowspan="1" colspan="1">&#8722;1.39</td><td rowspan="1" colspan="1">0.87</td><td rowspan="1" colspan="1">&#8722;1.60</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">2.49</td><td rowspan="1" colspan="1">0.55</td><td rowspan="1" colspan="1">4.50</td><td rowspan="1" colspan="1">4.1e&#8722;05</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">&#8722;2.34</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">&#8722;4.32</td><td rowspan="1" colspan="1">6.3e&#8722;05</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">&#8722;0.36</td><td rowspan="1" colspan="1">1.45</td><td rowspan="1" colspan="1">&#8722;0.24</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">Ns</td></tr><tr><td colspan="6" rowspan="1">
<bold>MAAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;1.70</td><td rowspan="1" colspan="1">1.66</td><td rowspan="1" colspan="1">&#8722;1.03</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after infection</td><td rowspan="1" colspan="1">0.44</td><td rowspan="1" colspan="1">1.90</td><td rowspan="1" colspan="1">0.23</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 30&#8211;39</td><td rowspan="1" colspan="1">&#8722;0.20</td><td rowspan="1" colspan="1">1.65</td><td rowspan="1" colspan="1">&#8722;0.12</td><td rowspan="1" colspan="1">0.2</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 40&#8211;49</td><td rowspan="1" colspan="1">&#8722;4.36</td><td rowspan="1" colspan="1">1.86</td><td rowspan="1" colspan="1">&#8722;2.34</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age &gt;50</td><td rowspan="1" colspan="1">&#8722;8.76</td><td rowspan="1" colspan="1">2.33</td><td rowspan="1" colspan="1">&#8722;3.76</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">4.62</td><td rowspan="1" colspan="1">1.48</td><td rowspan="1" colspan="1">3.12</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">&#8722;5.75</td><td rowspan="1" colspan="1">1.45</td><td rowspan="1" colspan="1">&#8722;3.96</td><td rowspan="1" colspan="1">4.7e&#8722;06</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">&#8722;1.36</td><td rowspan="1" colspan="1">3.89</td><td rowspan="1" colspan="1">&#8722;0.35</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="6" rowspan="1">
<bold>GAD-7</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.90</td><td rowspan="1" colspan="1">0.56</td><td rowspan="1" colspan="1">&#8722;1.61</td><td rowspan="1" colspan="1">0.46</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.45</td><td rowspan="1" colspan="1">0.64</td><td rowspan="1" colspan="1">&#8722;0.70</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 30&#8211;39</td><td rowspan="1" colspan="1">&#8722;0.92</td><td rowspan="1" colspan="1">0.56</td><td rowspan="1" colspan="1">&#8722;1.65</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 40&#8211;49</td><td rowspan="1" colspan="1">&#8722;0.05</td><td rowspan="1" colspan="1">0.63</td><td rowspan="1" colspan="1">&#8722;0.07</td><td rowspan="1" colspan="1">0.036</td><td rowspan="1" colspan="1">*</td></tr><tr><td rowspan="1" colspan="1">Age &gt;50</td><td rowspan="1" colspan="1">&#8722;1.11</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1">&#8722;1.42</td><td rowspan="1" colspan="1">0.00061</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">0.95</td><td rowspan="1" colspan="1">0.50</td><td rowspan="1" colspan="1">1.92</td><td rowspan="1" colspan="1">0.0044</td><td rowspan="1" colspan="1">**</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">&#8722;2.50</td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">&#8722;5.12</td><td rowspan="1" colspan="1">0.00041</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">&#8722;0.83</td><td rowspan="1" colspan="1">1.31</td><td rowspan="1" colspan="1">&#8722;0.63</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="6" rowspan="1">
<bold>PHQ-2</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.42</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">&#8722;2.02</td><td rowspan="1" colspan="1">0.067</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.20</td><td rowspan="1" colspan="1">0.24</td><td rowspan="1" colspan="1">&#8722;0.83</td><td rowspan="1" colspan="1">0.41</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 30&#8211;39</td><td rowspan="1" colspan="1">&#8722;0.51</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">&#8722;2.46</td><td rowspan="1" colspan="1">0.032</td><td rowspan="1" colspan="1">*</td></tr><tr><td rowspan="1" colspan="1">Age 40&#8211;49</td><td rowspan="1" colspan="1">&#8722;0.22</td><td rowspan="1" colspan="1">0.23</td><td rowspan="1" colspan="1">&#8722;0.94</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age &gt;50</td><td rowspan="1" colspan="1">&#8722;0.60</td><td rowspan="1" colspan="1">0.29</td><td rowspan="1" colspan="1">&#8722;2.04</td><td rowspan="1" colspan="1">0.067</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">&#160;0.67</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">3.60</td><td rowspan="1" colspan="1">0.0016</td><td rowspan="1" colspan="1">**</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">&#8722;0.58</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">&#8722;3.19</td><td rowspan="1" colspan="1">0.0046</td><td rowspan="1" colspan="1">**</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">&#8722;0.62</td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">&#8722;1.26</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="6" rowspan="1">
<bold>SSS-8</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;0.93</td><td rowspan="1" colspan="1">0.69</td><td rowspan="1" colspan="1">&#8722;1.35</td><td rowspan="1" colspan="1">0.27</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">&gt;4 weeks after infection</td><td rowspan="1" colspan="1">&#8722;1.63</td><td rowspan="1" colspan="1">0.80</td><td rowspan="1" colspan="1">&#8722;2.05</td><td rowspan="1" colspan="1">0.091</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 30&#8211;39</td><td rowspan="1" colspan="1">&#8722;0.49</td><td rowspan="1" colspan="1">0.69</td><td rowspan="1" colspan="1">&#8722;0.70</td><td rowspan="1" colspan="1">0.62</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age 40&#8211;49</td><td rowspan="1" colspan="1">0.23</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">0.86</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age &gt;50</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.96</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Sex (female)</td><td rowspan="1" colspan="1">2.88</td><td rowspan="1" colspan="1">0.62</td><td rowspan="1" colspan="1">4.65</td><td rowspan="1" colspan="1">1.5e&#8722;05</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">&#8722;3.31</td><td rowspan="1" colspan="1">0.61</td><td rowspan="1" colspan="1">&#8722;5.45</td><td rowspan="1" colspan="1">4.3e&#8722;07</td><td rowspan="1" colspan="1">***</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">&#8722;3.20</td><td rowspan="1" colspan="1">1.63</td><td rowspan="1" colspan="1">&#8722;1.96</td><td rowspan="1" colspan="1">0.091</td><td rowspan="1" colspan="1">ns</td></tr></tbody></table></table-wrap><table-wrap position="float" id="fcad092-T4" orientation="portrait"><label>Table&#160;4</label><caption><p>Summary statistics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">F</italic>-statistic</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>-value</th><th align="center" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">
<bold>FAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">2.57</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">0.60</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">0.33</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">
<bold>GAD-7</bold>
</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">0.31</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.68</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">0.35</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">0.46</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">
<bold>MAAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.91</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">0.41</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">
<bold>PHQ-2</bold>
</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">0.17</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.39</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">0.56</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">2.14</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">ns</td></tr><tr><td colspan="4" rowspan="1">
<bold>SSS-8</bold>
</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1">1.68</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">0.47</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Preconditions</td><td rowspan="1" colspan="1">3.67</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Vaccination</td><td rowspan="1" colspan="1">0.51</td><td rowspan="1" colspan="1">0.93</td><td rowspan="1" colspan="1">ns</td></tr></tbody></table></table-wrap><p>Since we observed significant differences in some of the scores between different age groups (<xref rid="fcad092-T5" ref-type="table">Table&#160;5</xref>), we performed correlation analyses of each score and time after recovery for all 263 infected individuals separated by age groups to rule out that certain age groups were affected by neuropsychiatric symptoms following SARS-CoV-2 infection while others were not. In accordance with our other findings, we did not observe significant correlations between time after infection and persistent somatic symptoms (<xref rid="fcad092-F2" ref-type="fig">Fig.&#160;2F&#8211;J</xref>) and neuropsychiatric deficits for each score (results are shown in <xref rid="fcad092-T5" ref-type="table">Table&#160;5</xref>). Furthermore, we tested for correlation between persistent symptoms and number of vaccinations, which was again not significant for each age group (results are shown in <xref rid="fcad092-T5" ref-type="table">Table&#160;5</xref>). We analysed the impact of re-infections on persistent symptoms by correlation analysis and detected no significant differences in both sexes (FAS: female, <italic toggle="yes">P</italic> = 0.10, <italic toggle="yes">R</italic> = &#8722;0.11; male, <italic toggle="yes">P</italic> = 0.30, <italic toggle="yes">R</italic> = &#8722;0.10; GAD-7: female, <italic toggle="yes">P</italic> = 0.92, <italic toggle="yes">R</italic> = 0.006; male, <italic toggle="yes">P</italic> = 0.09, <italic toggle="yes">R</italic> = &#8722;0.16; MAAS: female, <italic toggle="yes">P</italic> = 0.34, <italic toggle="yes">R</italic> = 0.06; male, <italic toggle="yes">P</italic> = 0.21, <italic toggle="yes">R</italic> = &#8722;0.12; PHQ-2: female, <italic toggle="yes">P</italic> = 0.62, <italic toggle="yes">R</italic> = &#8722;0.03; male, <italic toggle="yes">P</italic> = 0.07, <italic toggle="yes">R</italic> = &#8722;0.17; SSS-8: female, <italic toggle="yes">P</italic> = 0.07, <italic toggle="yes">R</italic> = &#8722;0.12; male, <italic toggle="yes">P</italic> = 0.55, <italic toggle="yes">R</italic> = &#8722;0.06). Last, we compared patients with one infection (<italic toggle="yes">n</italic> = 241) and re-infection (<italic toggle="yes">n</italic> = 22) and identified no significant differences in remaining somatic (SSS-8, <italic toggle="yes">P</italic> = 0.65) or neuropsychiatric symptoms (FAS, <italic toggle="yes">P</italic> = 0.40; GAD-7, <italic toggle="yes">P</italic> = 0.71; MAAS, <italic toggle="yes">P</italic> = 0.88; PHQ-2, <italic toggle="yes">P</italic> = 0.90) underlining the absence of post-acute neuropsychiatric deficits in individuals with up-to-date vaccination status after recovery from Omicron infection.</p><table-wrap position="float" id="fcad092-T5" orientation="portrait"><label>Table&#160;5</label><caption><p>Correlation analysis with sum scores and time after recovery and number of vaccinations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Time after recovery</th><th align="center" rowspan="1" colspan="1">Number of vaccinations</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">
<bold>FAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;30 years</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#8722;0.13</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39 years</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#8722;0.03</td></tr><tr><td rowspan="1" colspan="1">&gt;50 years</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">&#8722;0.03</td></tr><tr><td colspan="3" rowspan="1">
<bold>GAD&#8211;7</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;30 years</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#8722;0.13</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39 years</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#8722;0.02</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">&#8722;0.07</td></tr><tr><td rowspan="1" colspan="1">&gt;50 years</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">0.05</td></tr><tr><td colspan="3" rowspan="1">
<bold>MAAS</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;30 years</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">&#8722;0.07</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39 years</td><td rowspan="1" colspan="1">&#8722;0.004</td><td rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">0.19</td></tr><tr><td rowspan="1" colspan="1">&gt;50 years</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">&#8722;0.16</td></tr><tr><td colspan="3" rowspan="1">
<bold>PHQ-2</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;30 years</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">&#8722;0.08</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39 years</td><td rowspan="1" colspan="1">&#8722;0.08</td><td rowspan="1" colspan="1">&#8722;0.12</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">&gt;50 years</td><td rowspan="1" colspan="1">0.32</td><td rowspan="1" colspan="1">&#8722;0.2</td></tr><tr><td colspan="3" rowspan="1">
<bold>SSS&#8211;8</bold>
</td></tr><tr><td rowspan="1" colspan="1">&lt;30 years</td><td rowspan="1" colspan="1">&#8722;0.05</td><td rowspan="1" colspan="1">&#8722;0.09</td></tr><tr><td rowspan="1" colspan="1">30&#8211;39 years</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.04</td></tr><tr><td rowspan="1" colspan="1">40&#8211;49 years</td><td rowspan="1" colspan="1">&#8722;0.24</td><td rowspan="1" colspan="1">&#8722;0.21</td></tr><tr><td rowspan="1" colspan="1">&gt;50 years</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">&#8722;0.17</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="fcad092-s3"><title>Discussion</title><p>In this cross-sectional single-centre study, we investigated self-reported neuropsychiatric and somatic symptoms in individuals who experienced a mild breakthrough infection with the SARS-CoV-2 variant Omicron as compared with uninfected controls in a cohort of German hospital workers mostly having an up-to-date vaccination status. We used a comprehensive online questionnaire, addressing common neuropsychiatric symptoms including fatigue, attention deficits, depression and anxiety as well as the self-reported burden of somatic symptoms. For these symptoms, we did not detect any significant differences between individuals less and more than 4 weeks after infection with SARS-CoV-2 and uninfected controls after adjustment for sex, age, number of preconditions and vaccination against SARS-CoV-2.</p><p>Our results are in contrast to previous studies that report frequent and severe post-acute sequelae of COVID-19 during the first phases of the pandemic.<sup><xref rid="fcad092-B3" ref-type="bibr">3</xref>,<xref rid="fcad092-B39" ref-type="bibr">39</xref>,<xref rid="fcad092-B40" ref-type="bibr">40</xref></sup> Recent meta-analyses and systematic reviews revealed that more than half of individuals experienced at least one symptom after recovery from SARS-CoV-2 infection that persisted for more than 6 months with mobility impairment, pulmonary abnormalities and mental health disorders being the most common.<sup><xref rid="fcad092-B40" ref-type="bibr">40</xref></sup> Furthermore, several publications showed that neuropsychiatric deficits occur independently of the severity of the initial infection.<sup><xref rid="fcad092-B9" ref-type="bibr">9</xref>,<xref rid="fcad092-B18" ref-type="bibr">18</xref>,<xref rid="fcad092-B40" ref-type="bibr">40</xref></sup> However, these studies were conducted at a time when mainly the Wild-Type, Alpha, Beta and Delta variants of SARS-CoV-2 were prevalent, vaccination was not available, and Omicron had not yet emerged. In contrast, cross-sectional studies that correlated cerebral imaging with neuropsychological deficits reported no differences associated with the Wild-Type variant during the first wave.<sup><xref rid="fcad092-B41" ref-type="bibr">41</xref></sup> Clinical characterization of individuals after recovery from infection with Omicron is of utmost importance since it became the predominant variant worldwide due to high infectivity and poor cross-reactivity of available vaccinations.<sup><xref rid="fcad092-B42" ref-type="bibr">42</xref>,<xref rid="fcad092-B43" ref-type="bibr">43</xref></sup> It is unclear, whether the Omicron variant leads to persistent or novel neuropsychiatric and somatic symptoms after recovery from acute infection. Here, we demonstrate that vaccinated hospital workers after recovery from mild infection with Omicron do not have a higher burden of symptoms than hospital workers who never experienced SARS-CoV-2 infection. This is further supported by a recent study that analysed data from the COVID Symptoms Study app in the UK and showed that the risk of developing Long COVID was significantly lower in individuals who were infected with the Omicron variant compared with those infected with the Delta variant.<sup><xref rid="fcad092-B44" ref-type="bibr">44</xref></sup></p><p>The mechanistic underpinnings of Long COVID after infection with the Wild-Type, Alpha, Beta and Delta variants remain unclear. Neuropsychiatric deficits during the acute infection might be on the one hand explained by SARS-CoV-2&#8211;induced dysregulation of multiple organ systems<sup><xref rid="fcad092-B45" ref-type="bibr">45</xref></sup> and on the other hand by direct invasion of the central nervous system (CNS).<sup><xref rid="fcad092-B46" ref-type="bibr">46</xref>,<xref rid="fcad092-B47" ref-type="bibr">47</xref></sup> Although <italic toggle="yes">in vitro</italic> studies suggested neuronal tropism of SARS-CoV-2, post-mortem analyses of large cohorts could only identify SARS-CoV-2 by PCR or immunohistochemical staining of its capsid protein in the blood vessels and endothelial cells in the CNS,<sup><xref rid="fcad092-B48" ref-type="bibr">48</xref>,<xref rid="fcad092-B49" ref-type="bibr">49</xref></sup> together with bystander immune cell activation<sup><xref rid="fcad092-B50" ref-type="bibr">50</xref>,<xref rid="fcad092-B51" ref-type="bibr">51</xref></sup> but without parenchymal infiltration or neuronal infection. Additionally, there is no evidence of long-lasting persistence of SARS-CoV-2 in the CNS. On a systems level, elevated concentrations of the cytokine CCL11 were detected in individuals suffering from Long COVID as compared with those who experienced no symptoms following infection. Subsequent studies in mice suggest that CCL11 leads to white matter enriched microglial reactivity followed by a dysregulation of the oligodendroglial lineage and myelin loss.<sup><xref rid="fcad092-B19" ref-type="bibr">19</xref></sup> Other hypotheses include microclot formation in the blood<sup><xref rid="fcad092-B52" ref-type="bibr">52</xref></sup> and immunological dysfunctions following infection with a lack of na&#239;ve B and T cells as well as elevated expression of type I and III interferons.<sup><xref rid="fcad092-B53" ref-type="bibr">53</xref></sup> However, these studies did not analyse infection with the Omicron variant and lack specificity for SARS-CoV-2 since individuals after recovery from infection with other common viruses such as influenza virus were not investigated. Furthermore, we consider it important to include individuals who have not been infected as controls since the neuropsychiatric and somatic symptoms that are associated with Long COVID are unspecific, highly prevalent in the general population and could be exacerbated by the pandemic itself with its fundamental impact on daily living.<sup><xref rid="fcad092-B54" ref-type="bibr">54</xref></sup> Furthermore, Long COVID is currently a constant topic in the media that could contribute to overestimation of its prevalence and foster heightened attention in infected individuals.<sup><xref rid="fcad092-B55" ref-type="bibr">55</xref></sup> Studies as ours might therefore help mitigate negative expectations in susceptible individuals.</p><p>Our study is limited by its cross-sectional monocentric design without longitudinal follow-up and limited sample size. We therefore calculated the difference in means for each questionnaire that could have been undetected using our sample size. However, we included a healthy control group without SARS-CoV-2 infection and did not identify differences in comparison with individuals after recovery from infection. Our study focused on hospital workers, potentially leading to selection bias since this cohort might be specifically vulnerable to develop persistent symptoms of SARS-CoV-2 infection due to the heightened workload and pressure of medical staff resulting from the pandemic and increased attention to symptoms. However, both infected and uninfected individuals reached scores mostly within the physiological range for all questionnaires. One possible explanation is the inclusion of asymptomatic infections and the better position of hospital workers to mitigate symptoms. Furthermore, we analysed self-reported symptoms, which were not affirmed through clinical examination or diagnostic tools by healthcare professionals and are potentially prone to selection bias. However, one advantage of this approach is that it facilitates the investigation of symptoms and disease burden in a large number of individuals in an unbiased and cost-effective manner. Thus, this approach has the potential to perform population-based screens to assess prevalence of post-acute sequelae. For the future, standardized questionnaires to quantify persistent neuropsychiatric symptoms after infection with SARS-CoV-2 would be desirable. Since most of the participants were vaccinated at the time of the survey, it is difficult to discriminate whether the absence of self-reported post-acute neuropsychiatric and somatic symptoms is due to vaccination or if the Omicron variant of SARS-CoV-2 is less likely to cause these symptoms. The latter is supported by a large cohort study where vaccination showed no effect on post-COVID fatigue, cognitive symptoms or affective disorders before the emergence of the Omicron variant.<sup><xref rid="fcad092-B56" ref-type="bibr">56</xref></sup> In our study, we did not discriminate between Omicron subvariants. This should be systematically investigated by future studies due to the high escape of especially the BA.5 subvariant against neutralizing antibodies<sup><xref rid="fcad092-B57" ref-type="bibr">57</xref></sup> that might result in higher acute and persistent disease burden. Our cross-sectional study was restricted to hospital workers, and we cannot exclude a population bias. Nonetheless, our findings are supported by other studies that compared self-reported symptoms after infection with the Omicron and Delta variants and reported fewer individuals with long-lasting symptoms after Omicron infection.<sup><xref rid="fcad092-B44" ref-type="bibr">44</xref></sup> Furthermore, we did not have serological data for our control group available, and they were included due to self-reportedly denying past infection and the absence of positive SARS-CoV-2 PCRs in their medical history. The close monitoring of SARS-CoV-2 positivity by PCR in our cohort enabled us to sensitively identify individuals with mild disease or asymptomatic infection.</p></sec><sec id="fcad092-s4"><title>Conclusion</title><p>In summary, our data allow us to conclude that vaccinated hospital workers after recovery from mild infection with the Omicron variant of SARS-CoV-2 do not suffer from persistent somatic and neuropsychiatric symptoms in our study cohort. These findings have wide clinical implications and will guide occupational health specialists and other public health specialists in the management of potential Long COVID patients after recovery from Omicron infection.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>The authors thank the UKE ID COVID-19 study team for their support. They thank members of the Friese and Schulze zur Wiesch laboratories for discussions.</p></ack><sec id="fcad092-s5"><title>Funding</title><p>This work was funded by the &#8216;Deutsche Zentrum f&#252;r Infektionsforschung (DZIF)&#8217; (FKZ8009801908 to M.M.A., Fasttrack 1.921 to M.M.A.) and &#8216;Deutsche Forschungsgemeinschaft (DFG)&#8217; (FR1720/18-1 to M.A.F., SFB1328 to J.S.Z.W.). M.S.W. is supported by Joachim-Herz-Foundation.</p></sec><sec sec-type="COI-statement" id="fcad092-s6"><title>Competing interests</title><p>The authors declare no competing interests and no conflict of interest. MAF received honoraria for consultation and travel expenses from Biogen, Merck KGaA, Novartis and Roche unrelated to this work.</p></sec><sec sec-type="data-availability" id="fcad092-s7"><title>Data availability</title><p>Data are available from the corresponding author, upon reasonable request. Data are not publicly available due to ethical restrictions because the information contained in those data could compromise the privacy of the reported patients.</p></sec><app-group><app id="app1"><title>Appendix I.</title><p>Online questionnaires.</p><p>How old are you?</p><p>&lt;20</p><p>20&#8211;29</p><p>30&#8211;39</p><p>40&#8211;49</p><p>50&#8211;59</p><p>60&#8211;69</p><p>&gt;69</p><p>What is your gender?</p><p>Female</p><p>Male</p><p>Diverse</p><p>Do you suffer from any pre-existing medical conditions? Please select all that apply.</p><p>Heart attack</p><p>Heart failure</p><p>Peripheral artery disease (PAD)</p><p>Chronic obstructive pulmonary disease (COPD)</p><p>Asthma bronchiale</p><p>Gastric or duodenal ulcer</p><p>Mild liver disease</p><p>Moderate to severe liver disease</p><p>Moderate to severe renal failure</p><p>Collagenosis</p><p>Diabetes mellitus without end organ damage</p><p>Diabetes mellitus with end-organ damage</p><p>Stroke or transient ischaemic attack (TIA)</p><p>Hemiplegia</p><p>Multiple sclerosis</p><p>Migraine</p><p>Other headache disorder</p><p>Tumour disease (non-metastatic)</p><p>Tumour disease (metastasized)</p><p>Leukaemia</p><p>Lymphoma</p><p>AIDS</p><p>Dementia</p><p>Depression</p><p>Anxiety disorder</p><p>Other previous psychiatric illness</p><p>Other chronic infectious disease</p><p>Other autoimmune disease</p><p>How many COVID-19 vaccine doses did you receive to date?</p><p>0</p><p>1</p><p>2</p><p>3</p><p>4</p><p>When did you receive your first COVID-19 vaccination?</p><p>Month/year</p><p>Which COVID-19 vaccine did you receive for the first dose?</p><p>BioNTech/Pfizer</p><p>Moderna</p><p>AstraZeneca</p><p>Johnson &amp; Johnson</p><p>I do not know</p><p>Other</p><p>When did you receive your second COVID-19 vaccination?</p><p>Month/year</p><p>Which COVID-19 vaccine did you receive for the second dose?</p><p>BioNTech/Pfizer</p><p>Moderna</p><p>AstraZeneca</p><p>Johnson &amp; Johnson</p><p>I do not know</p><p>Other</p><p>When did you receive your third COVID-19 vaccination?</p><p>Month/year</p><p>Which COVID-19 vaccine did you receive for the third dose?</p><p>BioNTech/Pfizer</p><p>Moderna</p><p>AstraZeneca</p><p>Johnson &amp; Johnson</p><p>I do not know</p><p>Other</p><p>When did you receive your fourth COVID-19 vaccination?</p><p>Month/year</p><p>Which COVID-19 vaccine did you receive for the fourth dose?</p><p>BioNTech/Pfizer</p><p>Moderna</p><p>AstraZeneca</p><p>Johnson &amp; Johnson</p><p>I do not know</p><p>Other</p><p>Did you have contract or more SARS-CoV-2 infections diagnosed by PCR in the past?</p><p>No</p><p>Yes, one infection</p><p>Yes, two infections</p><p>Yes, three infections</p><p>When did you contract the first SARS-CoV-2 infection?</p><p>Month/year</p><p>How many COVID-19 vaccine doses had you received at the time of your first SARS-CoV-2 infection?</p><p>None</p><p>1</p><p>2</p><p>3</p><p>4</p><p>With which variant did you become infected at the time of your first SARS-CoV-2 infection?</p><p>Wild Type</p><p>Alpha</p><p>Beta</p><p>Gamma</p><p>Delta</p><p>Omicron</p><p>Not known</p><p>Did you require inpatient medical treatment at the time of your first SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>Did you require intensive care treatment at the time of your first SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>When did you contract the second SARS-CoV-2 infection?</p><p>Month/year</p><p>How many COVID-19 vaccine doses had you received at the time of your second SARS-CoV-2 infection?</p><p>None</p><p>1</p><p>2</p><p>3</p><p>4</p><p>With which variant did you become infected at the time of your second SARS-CoV-2 infection?</p><p>Wild Type</p><p>Alpha</p><p>Beta</p><p>Gamma</p><p>Delta</p><p>Omicron</p><p>Not known</p><p>Did you require inpatient medical treatment at the time of your second SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>Did you require intensive care treatment at the time of your second SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>When did you contract the third SARS-CoV-2 infection?</p><p>Month/year</p><p>How many COVID-19 vaccine doses had you received at the time of third SARS-CoV-2 infection?</p><p>None</p><p>1</p><p>2</p><p>3</p><p>4</p><p>With which variant did you become infected at the time of your third SARS-CoV-2 infection?</p><p>Wild Type</p><p>Alpha</p><p>Beta</p><p>Gamma</p><p>Delta</p><p>Omicron</p><p>Not known</p><p>Did you require inpatient medical treatment at the time of your third SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>Did you require intensive care treatment at the time of your third SARS-CoV-2 infection?</p><p>Yes</p><p>No</p><p>During the past 7 days, how much have you been bothered by any of the following problems?</p><p>(not at all; a little bit; somewhat; quite a bit; very much)</p><p>Stomach or bowel problems</p><p>Back pain</p><p>Pain in your arms, legs or joints</p><p>Headaches</p><p>Chest pain or shortness of breath</p><p>Dizziness</p><p>Feeling tired or having low energy</p><p>Trouble sleeping</p><p>Over the last 2 weeks, how often have you been bothered by any of the following problems?</p><p>(not at all; several days; more than half the days; nearly every day)</p><p>Little interest or pleasure in doing things</p><p>Feeling down, depressed or hopeless</p><p>Feeling nervous, anxious or on edge?</p><p>Not being able to stop or control worrying?</p><p>Worrying too much about different things?</p><p>Trouble relaxing?</p><p>Being so restless that it is hard to sit still?</p><p>Becoming easily annoyed or irritable?</p><p>Feeling afraid as if something awful might happen?</p><p>The following ten statements refer to how you usually feel. Per statement you can choose one out of five answer categories, varying from never to always.</p><p>(never; sometimes/about monthly or less; regularly/about a few times a month; often/about weekly; always/about every day)</p><p>I am bothered by fatigue</p><p>I get tired very quickly</p><p>I don&#8217;t do much during the day</p><p>I have enough energy for everyday life</p><p>Physically, I feel exhausted</p><p>I have problems to start things</p><p>I have problems to think clearly</p><p>I feel no desire to do anything</p><p>Mentally, I feel exhausted</p><p>When I am doing something, I can concentrate quite well</p><p>Below is a collection of statements about your everyday experience. Using the 1&#8211;6 scale below, please indicate how frequently or infrequently you currently have each experience. Please answer according to what really reflects your experience rather than what you think your experience should be. Please treat each item separately from every other item.</p><p>(1, almost always; 2, very frequently; 3, somewhat frequently; 4, somewhat infrequently; 5, very infrequently; 6, almost never)</p><p>I could be experiencing some emotion and not be conscious of it until some time later.</p><p>I break or spill things because of carelessness, not paying attention or thinking of something else.</p><p>I find it difficult to stay focused on what&#8217;s happening in the present.</p><p>I tend to walk quickly to get where I&#8217;m going without paying attention to what I experience along the way.</p><p>I tend not to notice feelings of physical tension or discomfort until they really grab my attention.</p><p>I forget a person&#8217;s name almost as soon as I&#8217;ve been told it for the first time.</p><p>It seems I am &#8216;running on automatic&#8217;, without much awareness of what I&#8217;m doing.</p><p>I rush through activities without being really attentive to them.</p><p>I get so focused on the goal I want to achieve that I lose touch with what I&#8217;m doing right now to get there.</p><p>I do jobs or tasks automatically, without being aware of what I&#8217;m doing.</p><p>I find myself listening to someone with one ear, doing something else at the same time.</p><p>I drive places on &#8216;automatic pilot&#8217; and then wonder why I went there.</p><p>I find myself preoccupied with the future or the past.</p><p>I find myself doing things without paying attention.</p><p>I snack without being aware that I&#8217;m eating.</p></app></app-group><ref-list id="ref1"><title>References</title><ref id="fcad092-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>von Felden</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brehm</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Schulze zur Wiesch</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Erratum zu: Milde COVID-19-Verl&#228;ufe bei Mitarbeitenden einer Universit&#228;tsklinik</article-title>. <source>Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz</source>. <year>2022</year>;<volume>65</volume>(<issue>3</issue>):<fpage>398</fpage>&#8211;<lpage>398</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00103-021-03406-w</pub-id><pub-id pub-id-type="pmcid">PMC8443902</pub-id><pub-id pub-id-type="pmid">34529097</pub-id></mixed-citation></ref><ref id="fcad092-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petersen</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Go&#223;ling</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group><article-title>Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme</article-title>. <source>Eur Heart J</source>. <year>2022</year>;<volume>43</volume>(<issue>11</issue>):<fpage>1124</fpage>&#8211;<lpage>1137</lpage>.<pub-id pub-id-type="pmid">34999762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehab914</pub-id><pub-id pub-id-type="pmcid">PMC8755397</pub-id></mixed-citation></ref><ref id="fcad092-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hampshire</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Trender</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chamberlain</surname><given-names>SR</given-names></string-name>, <etal>et al</etal></person-group><article-title>Cognitive deficits in people who have recovered from COVID-19</article-title>. <source>EClinicalMedicine</source>. <year>2021</year>;<volume>39</volume>:<fpage>101044</fpage>.<pub-id pub-id-type="pmid">34316551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101044</pub-id><pub-id pub-id-type="pmcid">PMC8298139</pub-id></mixed-citation></ref><ref id="fcad092-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Aly</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bowe</surname><given-names>B</given-names></string-name></person-group>. <article-title>High-dimensional characterization of post-acute sequelae of COVID-19</article-title>. <source>Nature</source>. <year>2021</year>;<volume>594</volume>(<issue>7862</issue>):<fpage>259</fpage>&#8211;<lpage>264</lpage>.<pub-id pub-id-type="pmid">33887749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03553-9</pub-id></mixed-citation></ref><ref id="fcad092-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sudre</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Varsavsky</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group><article-title>Attributes and predictors of Long COVID</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>4</issue>):<fpage>626</fpage>&#8211;<lpage>631</lpage>.<pub-id pub-id-type="pmid">33692530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01292-y</pub-id><pub-id pub-id-type="pmcid">PMC7611399</pub-id></mixed-citation></ref><ref id="fcad092-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sivan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>S</given-names></string-name></person-group>. <article-title>NICE guideline on Long COVID</article-title>. <source>BMJ</source>. <year>2020</year>;<volume>371</volume>:<fpage>m4938</fpage>.<pub-id pub-id-type="pmid">33361141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.m4938</pub-id></mixed-citation></ref><ref id="fcad092-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crook</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Raza</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nowell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Edison</surname><given-names>P</given-names></string-name></person-group>. <article-title>Long COVID&#8212;Mechanisms, risk factors, and management</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>374</volume>:<fpage>n1648</fpage>.<pub-id pub-id-type="pmid">34312178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n1648</pub-id></mixed-citation></ref><ref id="fcad092-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davis</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Assaf</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>McCorkell</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group><article-title>Characterizing Long COVID in an international cohort: 7 months of symptoms and their impact</article-title>. <source>EClinicalMedicine</source>. <year>2021</year>;<volume>38</volume>:<fpage>101019</fpage>.<pub-id pub-id-type="pmid">34308300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.101019</pub-id><pub-id pub-id-type="pmcid">PMC8280690</pub-id></mixed-citation></ref><ref id="fcad092-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Logue</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Franko</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>McCulloch</surname><given-names>DJ</given-names></string-name>, <etal>et al</etal></person-group><article-title>Sequelae in adults at 6 months after COVID-19 infection</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>2</issue>):<fpage>e210830</fpage>.<pub-id pub-id-type="pmid">33606031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.0830</pub-id><pub-id pub-id-type="pmcid">PMC7896197</pub-id></mixed-citation></ref><ref id="fcad092-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>EY</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Diverse functional autoantibodies in patients with COVID-19</article-title>. <source>Nature</source>. <year>2021</year>;<volume>595</volume>(<issue>7866</issue>):<fpage>283</fpage>&#8211;<lpage>288</lpage>.<pub-id pub-id-type="pmid">34010947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03631-y</pub-id></mixed-citation></ref><ref id="fcad092-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rojas</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Acosta-Ampudia</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group><article-title>Autoimmunity is a hallmark of post-COVID syndrome</article-title>. <source>J Transl Med</source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>129</fpage>.<pub-id pub-id-type="pmid">35296346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-022-03328-4</pub-id><pub-id pub-id-type="pmcid">PMC8924736</pub-id></mixed-citation></ref><ref id="fcad092-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>DG</given-names></string-name>, <etal>et al</etal></person-group><article-title>Multiple early factors anticipate post-acute COVID-19 sequelae</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>(<issue>5</issue>):<fpage>881</fpage>&#8211;<lpage>895.e20</lpage>.<pub-id pub-id-type="pmid">35216672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.01.014</pub-id><pub-id pub-id-type="pmcid">PMC8786632</pub-id></mixed-citation></ref><ref id="fcad092-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moriguchi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Harii</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goto</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>A first case of meningitis/encephalitis associated with SARS-coronavirus-2</article-title>. <source>Int J Infect Dis</source>. <year>2020</year>;<volume>94</volume>:<fpage>55</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">32251791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.03.062</pub-id><pub-id pub-id-type="pmcid">PMC7195378</pub-id></mixed-citation></ref><ref id="fcad092-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oxley</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Mocco</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Majidi</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Large-Vessel stroke as a presenting feature of COVID-19 in the young</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>20</issue>):<fpage>e60</fpage>.<pub-id pub-id-type="pmid">32343504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2009787</pub-id><pub-id pub-id-type="pmcid">PMC7207073</pub-id></mixed-citation></ref><ref id="fcad092-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nalleballe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Reddy Onteddu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title>Spectrum of neuropsychiatric manifestations in COVID-19</article-title>. <source>Brain Behav Immun</source>. <year>2020</year>;<volume>88</volume>:<fpage>71</fpage>&#8211;<lpage>74</lpage> .<pub-id pub-id-type="pmid">32561222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2020.06.020</pub-id><pub-id pub-id-type="pmcid">PMC7297688</pub-id></mixed-citation></ref><ref id="fcad092-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rogers</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Chesney</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group><article-title>Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic</article-title>. <source>Lancet Psychiatry</source>. <year>2020</year>;<volume>7</volume>(<issue>7</issue>):<fpage>611</fpage>&#8211;<lpage>627</lpage>.<pub-id pub-id-type="pmid">32437679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30203-0</pub-id><pub-id pub-id-type="pmcid">PMC7234781</pub-id></mixed-citation></ref><ref id="fcad092-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varatharaj</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ellul</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study</article-title>. <source>Lancet Psychiatry</source>. <year>2020</year>;<volume>7</volume>(<issue>10</issue>):<fpage>875</fpage>&#8211;<lpage>882</lpage>.<pub-id pub-id-type="pmid">32593341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(20)30287-X</pub-id><pub-id pub-id-type="pmcid">PMC7316461</pub-id></mixed-citation></ref><ref id="fcad092-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Woo</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Malsy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>P&#246;ttgen</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Frequent neurocognitive deficits after recovery from mild COVID-19</article-title>. <source>Brain Commun</source>. <year>2020</year>;<volume>2</volume>(<issue>2</issue>):<fpage>fcaa205</fpage>.<pub-id pub-id-type="pmid">33376990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaa205</pub-id><pub-id pub-id-type="pmcid">PMC7717144</pub-id></mixed-citation></ref><ref id="fcad092-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fern&#225;ndez-Casta&#241;eda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Geraghty</surname><given-names>AC</given-names></string-name>, <etal>et al</etal></person-group><article-title>Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation</article-title>. <source>Cell</source>. <year>2022</year>;<volume>185</volume>:<fpage>2452</fpage>&#8211;<lpage>2468.e16</lpage> .<pub-id pub-id-type="pmid">35768006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.06.008</pub-id><pub-id pub-id-type="pmcid">PMC9189143</pub-id></mixed-citation></ref><ref id="fcad092-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Aly</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bowe</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Long COVID after breakthrough SARS-CoV-2 infection</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>:<fpage>1461</fpage>&#8211;<lpage>1467</lpage>.<pub-id pub-id-type="pmid">35614233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01840-0</pub-id><pub-id pub-id-type="pmcid">PMC9307472</pub-id></mixed-citation></ref><ref id="fcad092-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Juthani</surname><given-names>PV</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Borges</surname><given-names>KA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Hospitalisation among vaccine breakthrough COVID-19 infections</article-title>. <source>Lancet Infect Dis</source>. <year>2021</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1485</fpage>&#8211;<lpage>1486</lpage>.<pub-id pub-id-type="pmid">34506735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00558-2</pub-id><pub-id pub-id-type="pmcid">PMC8423430</pub-id></mixed-citation></ref><ref id="fcad092-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sormani</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Schiavetti</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Inglese</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy</article-title>. <source>eBioMedicine</source>. <year>2022</year>;<volume>80</volume>:<fpage>104042</fpage>.<pub-id pub-id-type="pmid">35526306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2022.104042</pub-id><pub-id pub-id-type="pmcid">PMC9069178</pub-id></mixed-citation></ref><ref id="fcad092-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coburn</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Humes</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title>Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>6</issue>):<fpage>e2215934</fpage>.<pub-id pub-id-type="pmid">35671054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.15934</pub-id><pub-id pub-id-type="pmcid">PMC9175076</pub-id></mixed-citation></ref><ref id="fcad092-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>R</given-names></string-name></person-group>. <article-title>Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021</article-title>. <source>World Psychiatry</source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>124</fpage>&#8211;<lpage>132</lpage>.<pub-id pub-id-type="pmid">34612005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wps.20921</pub-id><pub-id pub-id-type="pmcid">PMC8661963</pub-id></mixed-citation></ref><ref id="fcad092-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brehm</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ullrich</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group><article-title>Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic</article-title>. <source>Int J Hyg Environ Health</source>. <year>2021</year>;<volume>238</volume>:<fpage>113851</fpage>.<pub-id pub-id-type="pmid">34601375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijheh.2021.113851</pub-id><pub-id pub-id-type="pmcid">PMC8463331</pub-id></mixed-citation></ref><ref id="fcad092-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Vries</surname><given-names>J</given-names></string-name></person-group>. <article-title>Assessment of fatigue among working people: A comparison of six questionnaires</article-title>. <source>Occup Environ Med</source>. <year>2003</year>; <volume>60</volume>(Suppl 1):<fpage>10i</fpage>&#8211;<lpage>115</lpage>.<pub-id pub-id-type="pmid">12782741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/oem.60.suppl_1.i10</pub-id><pub-id pub-id-type="pmcid">PMC1765720</pub-id></mixed-citation></ref><ref id="fcad092-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horisberger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Courvoisier</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ribi</surname><given-names>C</given-names></string-name></person-group>. <article-title>The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: A cross-sectional study</article-title>. <source>Arthritis Res Ther</source>. <year>2019</year>;<volume>21</volume>(<issue>1</issue>):<fpage>80</fpage>.<pub-id pub-id-type="pmid">30909957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-019-1864-4</pub-id><pub-id pub-id-type="pmcid">PMC6434822</pub-id></mixed-citation></ref><ref id="fcad092-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Michielsen</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>De Vries</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Van Heck</surname><given-names>GL</given-names></string-name></person-group>. <article-title>Psychometric qualities of a brief self-rated fatigue measure</article-title>. <source>J Psychosom Res</source>. <year>2003</year>;<volume>54</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>352</lpage>.<pub-id pub-id-type="pmid">12670612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-3999(02)00392-6</pub-id></mixed-citation></ref><ref id="fcad092-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carlson</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>KW</given-names></string-name></person-group>. <article-title>Validation of the Mindful Attention Awareness Scale in a cancer population</article-title>. <source>J Psychosom Res</source>. <year>2005</year>;<volume>58</volume>(<issue>1</issue>):<fpage>29</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">15771867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychores.2004.04.366</pub-id></mixed-citation></ref><ref id="fcad092-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Ryan</surname><given-names>RM</given-names></string-name></person-group>. <article-title>The benefits of being present: Mindfulness and its role in psychological well-being</article-title>. <source>J Pers Soc Psychol</source>. <year>2003</year>;<volume>84</volume>(<issue>4</issue>):<fpage>822</fpage>&#8211;<lpage>848</lpage>.<pub-id pub-id-type="pmid">12703651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0022-3514.84.4.822</pub-id></mixed-citation></ref><ref id="fcad092-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JBW</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>B</given-names></string-name></person-group>. <article-title>An ultra-brief screening scale for anxiety and depression: The PHQ-4</article-title>. <source>Psychosomatics</source>. <year>2009</year>;<volume>50</volume>(<issue>6</issue>):<fpage>613</fpage>&#8211;<lpage>621</lpage>.<pub-id pub-id-type="pmid">19996233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.psy.50.6.613</pub-id></mixed-citation></ref><ref id="fcad092-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JBW</given-names></string-name>, <string-name name-style="western"><surname>L&#246;we</surname><given-names>B</given-names></string-name></person-group>. <article-title>A brief measure for assessing Generalized Anxiety Disorder</article-title>. <source>Arch Intern Med</source>. <year>2006</year>;<volume>166</volume>(<issue>10</issue>):<fpage>1092</fpage>.<pub-id pub-id-type="pmid">16717171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinte.166.10.1092</pub-id></mixed-citation></ref><ref id="fcad092-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>JBW</given-names></string-name>, <string-name name-style="western"><surname>Monahan</surname><given-names>PO</given-names></string-name>, <string-name name-style="western"><surname>L&#246;we</surname><given-names>B</given-names></string-name></person-group>. <article-title>Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection</article-title>. <source>Ann Intern Med</source>. <year>2007</year>;<volume>146</volume>(<issue>5</issue>):<fpage>317</fpage>.<pub-id pub-id-type="pmid">17339617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-146-5-200703060-00004</pub-id></mixed-citation></ref><ref id="fcad092-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gierk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kohlmann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>The Somatic Symptom Scale&#8211;8 (SSS-8)</article-title>. <source>JAMA Intern Med</source>. <year>2014</year>;<volume>174</volume>(<issue>3</issue>):<fpage>399</fpage>.<pub-id pub-id-type="pmid">24276929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2013.12179</pub-id></mixed-citation></ref><ref id="fcad092-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kortela</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kirjavainen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ahava</surname><given-names>MJ</given-names></string-name>, <etal>et al</etal></person-group><article-title>Real-life clinical sensitivity of SARS-CoV-2 RT-PCR test in symptomatic patients. Ricci S, ed</article-title>. <source>PLoS One</source>. <year>2021</year>;<volume>16</volume>(<issue>5</issue>):<fpage>e0251661</fpage>.<pub-id pub-id-type="pmid">34019562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0251661</pub-id><pub-id pub-id-type="pmcid">PMC8139477</pub-id></mixed-citation></ref><ref id="fcad092-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nagura-Ikeda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Imai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tabata</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Clinical evaluation of self-collected Saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription&#8211;loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19</article-title>. <source>J Clin Microbiol</source>. <year>2020</year>;<volume>58</volume>(<issue>9</issue>):<fpage>e01438-20</fpage>.<pub-id pub-id-type="pmid">32636214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JCM.01438-20</pub-id><pub-id pub-id-type="pmcid">PMC7448663</pub-id></mixed-citation></ref><ref id="fcad092-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pfefferle</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reucher</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>N&#246;rz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>L&#252;tgehetmann</surname><given-names>M</given-names></string-name></person-group>. <article-title>Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system</article-title>. <source>Eurosurveillance</source>. <year>2020</year>;<volume>25</volume>(<issue>9</issue>):<fpage>2000152</fpage>.<pub-id pub-id-type="pmid">32156329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2020.25.9.2000152</pub-id><pub-id pub-id-type="pmcid">PMC7068162</pub-id></mixed-citation></ref><ref id="fcad092-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Townsend</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dyer</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group><article-title>Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection.</article-title><person-group person-group-type="editor"><string-name name-style="western"><surname>Madeddu</surname><given-names>G</given-names></string-name></person-group>, ed. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>11</issue>):<fpage>e0240784</fpage>.<pub-id pub-id-type="pmid">33166287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0240784</pub-id><pub-id pub-id-type="pmcid">PMC7652254</pub-id></mixed-citation></ref><ref id="fcad092-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nasserie</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hittle</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>SN</given-names></string-name></person-group>. <article-title>Assessment of the frequency and variety of persistent symptoms among patients with COVID-19</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e2111417</fpage>.<pub-id pub-id-type="pmid">34037731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.11417</pub-id><pub-id pub-id-type="pmcid">PMC8155823</pub-id></mixed-citation></ref><ref id="fcad092-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Groff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ssentongo</surname><given-names>AE</given-names></string-name>, <etal>et al</etal></person-group><article-title>Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection</article-title>. <source>JAMA Netw Open</source>. <year>2021</year>;<volume>4</volume>(<issue>10</issue>):<fpage>e2128568</fpage>.<pub-id pub-id-type="pmid">34643720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.28568</pub-id><pub-id pub-id-type="pmcid">PMC8515212</pub-id></mixed-citation></ref><ref id="fcad092-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petersen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>N&#228;gele</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group><article-title>Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection</article-title>. <source>medRxiv</source>. <year>2022</year>.doi:<pub-id pub-id-type="doi">10.1101/2022.07.08.22277420</pub-id><pub-id pub-id-type="pmcid">PMC10235949</pub-id><pub-id pub-id-type="pmid">37220275</pub-id></mixed-citation></ref><ref id="fcad092-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quandt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Muik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Salisch</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group><article-title>1 Breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes</article-title>. <source>Sci Immunol</source>. <year>2022</year>;<volume>7</volume>:<fpage>eabq2427</fpage>.<pub-id pub-id-type="pmid">35653438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abq2427</pub-id><pub-id pub-id-type="pmcid">PMC9162083</pub-id></mixed-citation></ref><ref id="fcad092-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Larkin</surname><given-names>HD</given-names></string-name></person-group>. <article-title>Four vaccine doses prevented severe Omicron COVID-19 better than 3</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>327</volume>(<issue>18</issue>):<fpage>1748</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2022.7248</pub-id><pub-id pub-id-type="pmid">35536278</pub-id></mixed-citation></ref><ref id="fcad092-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Antonelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pujol</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Spector</surname><given-names>TD</given-names></string-name>, <string-name name-style="western"><surname>Ourselin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Steves</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Risk of Long COVID associated with delta versus Omicron variants of SARS-CoV-2</article-title>. <source>Lancet</source>. <year>2022</year>;<volume>399</volume>(<issue>10343</issue>):<fpage>2263</fpage>&#8211;<lpage>2264</lpage>.<pub-id pub-id-type="pmid">35717982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(22)00941-2</pub-id><pub-id pub-id-type="pmcid">PMC9212672</pub-id></mixed-citation></ref><ref id="fcad092-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Woo</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Haag</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nierhaus</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19</article-title>. <source>iScience</source>. <year>2021</year>;<volume>24</volume>(<issue>7</issue>):<fpage>102752</fpage>.<pub-id pub-id-type="pmid">34179733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102752</pub-id><pub-id pub-id-type="pmcid">PMC8213514</pub-id></mixed-citation></ref><ref id="fcad092-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Solomon</surname><given-names>IH</given-names></string-name>, <string-name name-style="western"><surname>Normandin</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharyya</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>Neuropathological features of COVID-19</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>:<fpage>989</fpage>&#8211;<lpage>992</lpage> .<pub-id pub-id-type="pmid">32530583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2019373</pub-id><pub-id pub-id-type="pmcid">PMC7304421</pub-id></mixed-citation></ref><ref id="fcad092-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matschke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>L&#252;tgehetmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hagel</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group><article-title>Neuropathology of patients with COVID-19 in Germany: A post-mortem case series</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>11</issue>):<fpage>919</fpage>&#8211;<lpage>929</lpage>.<pub-id pub-id-type="pmid">33031735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30308-2</pub-id><pub-id pub-id-type="pmcid">PMC7535629</pub-id></mixed-citation></ref><ref id="fcad092-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krasemann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haferkamp</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Pfefferle</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group><article-title>The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2</article-title>. <source>Stem Cell Reports</source>. <year>2022</year>;<volume>11</volume>(<issue>2</issue>):<fpage>578</fpage>&#8211;<lpage>592</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stemcr.2021.12.011</pub-id><pub-id pub-id-type="pmcid">PMC8772030</pub-id><pub-id pub-id-type="pmid">35063125</pub-id></mixed-citation></ref><ref id="fcad092-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varga</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Flammer</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Steiger</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10234</issue>):<fpage>1417</fpage>&#8211;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">32325026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30937-5</pub-id><pub-id pub-id-type="pmcid">PMC7172722</pub-id></mixed-citation></ref><ref id="fcad092-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Kern</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Losada</surname><given-names>PM</given-names></string-name>, <etal>et al</etal></person-group><article-title>Dysregulation of brain and choroid plexus cell types in severe COVID-19</article-title>. <source>Nature</source>. <year>2021</year>;<volume>595</volume>(<issue>7868</issue>):<fpage>565</fpage>&#8211;<lpage>571</lpage>.<pub-id pub-id-type="pmid">34153974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03710-0</pub-id><pub-id pub-id-type="pmcid">PMC8400927</pub-id></mixed-citation></ref><ref id="fcad092-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rutkai</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Hellmers</surname><given-names>LM</given-names></string-name>, <etal>et al</etal></person-group><article-title>Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>1745</fpage>.<pub-id pub-id-type="pmid">35365631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-29440-z</pub-id><pub-id pub-id-type="pmcid">PMC8975902</pub-id></mixed-citation></ref><ref id="fcad092-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leppkes</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Knopf</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Naschberger</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group><article-title>Vascular occlusion by neutrophil extracellular traps in COVID-19</article-title>. <source>EBioMedicine</source>. <year>2020</year>;<volume>58</volume>:<fpage>102925</fpage>.<pub-id pub-id-type="pmid">32745993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2020.102925</pub-id><pub-id pub-id-type="pmcid">PMC7397705</pub-id></mixed-citation></ref><ref id="fcad092-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Phetsouphanh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Darley</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>DB</given-names></string-name>, <etal>et al</etal></person-group><article-title>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection</article-title>. <source>Nat Immunol</source>. <year>2022</year>;<volume>23</volume>(<issue>2</issue>):<fpage>210</fpage>&#8211;<lpage>216</lpage>.<pub-id pub-id-type="pmid">35027728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-021-01113-x</pub-id></mixed-citation></ref><ref id="fcad092-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>L&#246;we</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Andresen</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Van den Bergh</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group><article-title>Persistent SOMAtic symptoms ACROSS diseases&#8212;From risk factors to modification: Scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211)</article-title>. <source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>e057596</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2021-057596</pub-id><pub-id pub-id-type="pmcid">PMC8785206</pub-id><pub-id pub-id-type="pmid">35063961</pub-id></mixed-citation></ref><ref id="fcad092-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matta</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wiernik</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Robineau</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group><article-title>Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic</article-title>. <source>JAMA Intern Med</source>. <year>2022</year>;<volume>182</volume>(<issue>1</issue>):<fpage>19</fpage>.<pub-id pub-id-type="pmid">34747982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2021.6454</pub-id><pub-id pub-id-type="pmcid">PMC8576624</pub-id></mixed-citation></ref><ref id="fcad092-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taquet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dercon</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>PJ</given-names></string-name></person-group>. <article-title>Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections</article-title>. <source>Brain Behav Immun</source>. <year>2022</year>;<volume>103</volume>:<fpage>154</fpage>&#8211;<lpage>162</lpage>.<pub-id pub-id-type="pmid">35447302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbi.2022.04.013</pub-id><pub-id pub-id-type="pmcid">PMC9013695</pub-id></mixed-citation></ref><ref id="fcad092-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hachmann</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Collier</surname><given-names>AY</given-names></string-name>, <etal>et al</etal></person-group><article-title>Neutralization Escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>1</issue>):<fpage>86</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">35731894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2206576</pub-id><pub-id pub-id-type="pmcid">PMC9258748</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>COVID-19 =</term><def><p>coronavirus SARS-CoV-2</p></def></def-item><def-item><term>FAS =</term><def><p>Fatigue Assessment Scale</p></def></def-item><def-item><term>FDR =</term><def><p>false discovery rate</p></def></def-item><def-item><term>GAD-7 =</term><def><p>Generalized Anxiety Disorder 7</p></def></def-item><def-item><term>MAAS =</term><def><p>Mindful Attention Awareness Scale</p></def></def-item><def-item><term>PHQ-2 =</term><def><p>Patient Health Questionnaire 2</p></def></def-item><def-item><term>RT-PCR =</term><def><p>reverse transcription polymerase chain reaction</p></def></def-item><def-item><term>SARS-CoV-2 =</term><def><p>severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>SSS-8 =</term><def><p>Somatic Symptom Scale 8</p></def></def-item><def-item><term>UKE =</term><def><p>University Medical Center Hamburg-Eppendorf</p></def></def-item></def-list></glossary></back></article></pmc-articleset>